ClinicalTrials.gg
Drug

Bimatoprost clinical trials

Also written LUMIGAN® and LATISSE®.

Includes 10 studies of Bimatoprost Ophthalmic Solution.

studies test it
87
open now
3
in phase 3
23
first study started
2001

How each study uses Bimatoprost is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Bimatoprost studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Mar 2001 · LUMIGAN · NDA 021275 (FDA, Drugs@FDA)
European Union
8 Mar 2002 · Lumigan · EMEA/H/C/000391 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Bimatoprost
17
Bimatoprost SR
6
Bimatoprost 0.01%
6
Bimatoprost 0.03%
6
LUMIGAN® 0.01%
5

Brand

LUMIGAN®
18
LATISSE®
6
DURYSTA
1

Development codes

AGN-192024
1

In one entry with another drug

Given together, or one or the other

bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)
2

Studies by the year they started

82 studies that test it; most in 2011 (12)

Studies that test Bimatoprost, by start year
YearStudies
20011
20023
20053
20061
20075
20082
20098
20109
201112
20121
20135
20148
20155
20167
20183
20193
20201
20212
20231
20241
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
6
Phase 2
15
Phase 3
23
Phase 4
39
No phase
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 61 · Other 26

Allergan (43) · AbbVie (4) · ForSight Vision5, Inc. (4) · Innovative Medical (4) · Duke University (2) · University of Miami (2) · Laboratoires Thea (1) · Ahmed Hassan Nouh MD (1)

Often tested with

Tested in the same studies.

Latanoprost (11) · Travoprost (11) · Timolol (10) · Brimonidine (3) · Dorzolamide (2) · Hypromellose Derivatives (2) · Brimonidine Tartrate, Timolol Maleate Drug Combination (1) · Simenepag isopropyl (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test Bimatoprost, phase 3 first.

Studies

Open first, then newest update. How each study uses Bimatoprost is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 87

See all 87 studies that test Bimatoprost →

Given beside what is tested · 3 — Bimatoprost is usual care or a partner of the new treatment
As the comparator · 10 — what is tested is compared with Bimatoprost

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call Bimatoprost · ClinicalTrials.gg INT006613

  • MeSH (NLM) D000069580BimatoprostConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) QXS94885MZBIMATOPROSTConfirmed FDA, NLM, Wikidata
  • RxNorm 283810Confirmed FDA, Wikidata
  • Wikidata Q2393348bimatoprostConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C47414BimatoprostOne source FDA
  • DrugBank DB00905One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.